Research on the Status Quo and Countermeasures of Human Resource Management Outsourcing in China’s Pharmaceutical Enterprises

Objective To explore the current situation of human resource management outsourcing in China’s pharmaceutical enterprises,and to put forward some suggestions for enterprises and the government.Methods The current situation of human resource management outsourcing in China’s pharmaceutical enterprises was analyzed through the method of literature research.Results and Conclusion At present,the status of human resource management outsourcing in China’s pharmaceutical companies is that the level of human resource outsourcing companies is not high,and there are no relevant industry norms and laws.The information asymmetry between pharmaceutical enterprises and outsourcing companies results in adverse selection and moral hazard.Besides,the different culture of pharmaceutical enterprises and outsourcing companies leads to inefficient communication between enterprises and employee.To solve these problems,the government should promote and improve industry norms and laws to regulate the market.In addition,enterprises should clarify the motivation for outsourcing and make good decision on the outsourcing content.Meanwhile,enterprises should strengthen communication with employees to eliminate employees’concerns.

Ten Top "Foreign-Funded" Pharmaceutical Enterprises

The first session of the appraisal campaign, which lasted seven months, for choosing ten top "foreign-funded" pharmaceutical enterprises nationwide concluded on June 21. The State Pharmaceutical AdminiStration issued award certificates to the ten "foreign-funded" pharmaceutical enterprises which had won the honour of the best ten title headed by Xian-Janssen Pharmaceutical Ltd. This is the first large scale comprehensive appraisal of business scale, economic results and product status of the "foreign-funded" pharmaceutical enterprises all over China, aiming

TOP 50 IN CHINA'S PHARMACEUTICAL ENTERPRISES

Ⅰ. Chemical pharmaceutical industrialenterprises(40):North China Pharmaceutical PlantSouth Pharmaceutical PlantHarbin Pharmaceutical Co.,Ltd.Northeast Pharmaceutical Corporation(Group)

Suggestions on Foreign Pharmaceutical Enterprises Dealing with China’s Drug Centralized Procurement - Taking the First Batch of Implementation Results as an Example

Objective To analyze the impact of the first batch of centralized drug procurement on foreign pharmaceutical enterprises since the national centralized drug procurement policy has brought great impact on pharmaceutical market,and put forward some suggestions on their marketing transformation in China.Methods Firstly,the documents of the drug centralized procurement were studied,and then the sales figures before and after the implementation of the policy were retrieved from MiNET.At the same time,the relevant business adjustment information of foreign pharmaceutical enterprises was collected for analysis.Results and Conclusion The sales of related products of foreign pharmaceutical enterprises have dropped sharply,so they have stripped off these products and reduced their staff.It is suggested that foreign pharmaceutical enterprises should adjust the structure of sales team,strengthen the layout of the market in the county,and accelerate the introduction of innovative drugs to cope with centralized drug procurement.

Strategic Research on Pharmaceutical Enterprises’ Participation in National Drug Centralized Procurement

Objective To study the influence of national drug centralized procurement policy on pharmaceutical enterprises manufacturing generic drugs and original drugs,so as to provide a reference for them to make different strategic choices.Methods Through the literature research on the related policies and the bidding data,the national drug centralized policies were studied systematically.Combined with the bid-winning price and price reduction range of the winning enterprises in the three rounds of centralized procurement,their difficulties,strategic choices and the winning factors were investigated.Besides,a model was established to clarify the optimal price of enterprises in the process of drug procurement.Results and Conclusion The strategic choices of enterprises in participating national drug centralized procurement are influenced by many factors such as the market share of the original varieties,active pharmaceutical ingredients(APIs)and cost.Therefore,corresponding strategies should be formulated according to the characteristics and interests of enterprises.

The Impact of Generic Drug Consistency Evaluation Policy on Pharmaceutical Enterprises

Objective To study the impact of consistency evaluation policy on pharmaceutical enterprises from four aspects:reference preparations,evaluation methods,input costs,and market competitions,and government incentives for generic drug manufacturers,so as to put forward relevant suggestions.Methods Literature research method and statistical analysis method were used to provide data support for paper writing,making suggestions,and enhancing the predictability of policy.Results and Conclusion Some pharmaceutical enterprises faced difficulties in obtaining reference preparations,high input costs for exploring evaluation methods,and greater market competition.Consistency evaluation is a key measure to comprehensively improve the quality and efficacy of generic drugs.However,difficulties in obtaining reference preparations,high input costs and complex evaluation methods all affect the enthusiasm of companies.Therefore,national and local regulatory agencies have issued some supporting policies,which should be improved to assist enterprises in conducting consistency evaluations.

The Development of DTP Pharmacy and Its Impact on Pharmaceutical Enterprises

Objective To summarize the development status of direct to patient(DTP)pharmacy and its impact on pharmaceutical enterprises in China and to provide a reference for the pharmaceutical industry.Methods Literature research method was used to research domestic and foreign journals and magazines.Then,all sorts of data were collected to make a comprehensive comparison.Combined with relevant national policies,the current situation and advantages of the DTP pharmacy were analyzed to study its impact on pharmaceutical enterprises.Results and Conclusion Although DTP pharmacies are in the exploratory stage in China,with the advancement of comprehensive medical and health reforms,several national policies have created a good environment for the development of DTP pharmacies.Therefore,DTP pharmacies are accelerating their construction with better market value.As DTP pharmacies gradually become mature,some pharmaceutical enterprises have deepened cooperation with DTP pharmacies to open new channels for drug management.However,from the perspective of some generic drug enterprises,DTP pharmacies have certain adverse effects on them.

Research on Problems and Countermeasures of Patent Evaluation System in Pharmaceutical Enterprises

Objective To provide some suggestions and countermeasures for improving the patent evaluation system in pharmaceutical enterprises.Methods Literature research method was used to collect the relevant documents of pharmaceutical enterprises and patent evaluation system,and then the problems of traditional patent evaluation methods for pharmaceutical patents were studied.Results and Conclusion The evaluation of pharmaceutical patents plays an important role for pharmaceutical enterprises.However,it is urgent to improve the pharmaceutical patent evaluation system because there are many difficulties in evaluating pharmaceutical patents,such as large fluctuation of patent value,strong subjective interference,the incomplete pharmaceutical information,unapplicable traditional evaluation method,and the insufficient role of evaluation agencies.Therefore,some suggestions are put forward:(1)The application of the real option method;(2)Developing evaluation institutions and training evaluation personnel;(3)Improving the laws and policies related to the evaluation of pharmaceutical patents;(4)Building a pharmaceutical patent evaluation database.

Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement

Objective To provide reference for the development strategy of China’s enterprises under the current policy background of generic drug consistency evaluation and volume procurement.Methods China’s current policies on generic drugs and market environment were analyzed and the development paths of international top pharmaceutical enterprises were studied as well.Results and Conclusion There are four transformation and upgrading paths for China’s pharmaceutical enterprises.First,they should invest more in innovation to realize the globalization of new drugs.Second,overseas patented new drugs should be introduced actively.Third,they must focus on the research and development of high-end generic drugs.Lastly,the transformation from active pharmaceutical ingredients into pharmaceutic preparation should be carried out quickly.Under the background of volume procurement,the pharmaceutical market pattern will be completely changed.The research and development capability and patented drugs will become the core competitive advantages of enterprises.

Research on the Relationship between the Profitability and R&D Investment of Enterprises of Different Scales in China’s Pharmaceutical Industry

Objective To analyze the relationship between the profitability of pharmaceutical enterprises of different scales and their R&D investment.Methods The data of China’s pharmaceutical manufacturing industry from 1995 to 2016 were selected to establish a vector auto-regression mode,and then an impulse response function and variance decomposition were used to analyze the data.Results and Conclusion For large-scale pharmaceutical enterprises,1%increase in R&D input will lead to 0.792%increase of their main business profit.For medium-sized enterprises,if their main business profit increases by 1%,their R&D input will increase by 0.965%.Therefore,if their R&D input increases by 1%,their main business profit will increase by 1.036%.The improvement of the profitability of large-scale pharmaceutical enterprises cannot promote the increase of R&D capital investment.But the increase of profitability from medium-sized enterprises can promote the increase of R&D capital investment.As a result,the increase of R&D capital investment of large and medium-sized enterprises can improve corporate profitability.

Research on Risk Identification of Supply Chain Management in Pharmaceutical Wholesale Enterprises——Taking Enterprise A as an Example

Objective To study the current situation of supply chain management in pharmaceutical wholesale enterprises so that supply chain risks can be identified effectively.Methods Through the analysis of the actual situation of enterprise A,combining with the supply chain problem of the enterprise,the enterprise supply chain risks were found out.Results and Conclusion With the development of pharmaceutical circulation industry,the competition among drug wholesalers has become increasingly fierce.For enterprises,the supply chain risks are increasing,and the traditional upstream and downstream supply risks are transformed into multiple-dimensional risks.The goal of carrying out supply chain risk identification in pharmaceutical wholesale enterprises is to enable key enterprises to discover and understand different types of risks in time so as to improve the management of supply chain.

Statistical Analysis of Defective Items of Pharmaceutical Wholesale Enterprises

Objective To provide some references and suggestions for promoting the healthy development of pharmaceutical wholesale enterprises,improving the scientific supervision level of the drug regulatory department and ensuring the quality of drugs in the circulation.Methods Retrieving the items on the official websites of the national and provincial drug regulatory departments from 2017 to 2019 that didn’t meet the requirements of the 2016 edition of the Good Supplying Practice in pharmaceutical wholesale enterprises under various inspections,the defective items were summarized and analyzed,and further study of the changes of defective items was conducted.Results and Conclusion 908 pharmaceutical wholesale enterprises had definite defective items,and 218 items violated the Guidelines for On-site Inspection of the Good Supplying Practice,with a cumulative frequency of 3874 defects.Defective items with high-frequency mainly occurred in storage and maintenance,facilities and equipment,personnel and training,general rules and sales.The average defect frequency in each pharmaceutical wholesale enterprises increased year by year,but the proportion of serious defective items decreased significantly.It is recommended that based on improving drug quality,pharmaceutical wholesale enterprises should strengthen personnel training to enhance their awareness of quality responsibility.Besides,the drug regulatory department should increase inspection and crackdown on illegal business operations and the deception of pharmaceutical wholesale enterprises.

Research on Corporate Social Responsibility Evaluation Based on Improved CRITIC-TOPSIS—A Case Study of Listed Companies in China’s Pharmaceutical Distribution Industry

Corporate social responsibility (CSR) has garnered considerable attention from countries, institutions, enterprises and social groups. However, the lack of research on CSR evaluation system for industries has impeded its development and construction across various industries. Therefore, given the close association of pharmaceutical distribution enterprises with personal health, there exists a pressing need to explore the CSR in this domain. This paper establishes a CSR evaluation index system for pharmaceutical distribution enterprises, employing a combination of documentary analysis and in-depth interviews. This index system comprises 7 CSR criterion layers (e.g., responsible governance and employee responsibility) and 56 index layers. 25 listed companies in China’s pharmaceutical distribution industry are chosen as research objects, and this study also establishes an evaluation model for the CSR of pharmaceutical distribution companies through the improved Criteria Importance Though Intercrieria Correlation (CRITIC) method combined with The Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) method. The empirical analysis reveals that the responsible governance criterion layer and the social development criterion layer demonstrate the best performance, while the supplier, customer and patient responsibility criterion layer exhibit the worst performance.

Can a Government Initiate Enterprise Reform to Improve Efficiency？ A Cross-Section Analysis of the Chinese Pharmaceutical Industry

This paper examines the privatization, implemented by the effects of state-owned enterprises （SOE） Chinese government in the 1990s, on enterprise efficiency for a sample of non-privatized SOEs and privatized ex-SOEs. The study calculates input-oriented DEA meta-frontier efficiency scores, after accounting for heterogeneity in technology across groups. These scores are used to test whether or not one group＇s technology dominates the other. A measure of additional input saving is also provided if these enterprises have access to unrestricted rneta-technology. The analysis of the Chinese pharmaceutical industry reveals that privatization has not improved enterprise efficiency, at least in the short run. Almost 56% of inputs could be proportionally saved if these privatized ex-SOEs had been efficient, relative to the recta-production technology while non-privatized SOEs could proportionally save only 51%. Privatized ex-SOEs had less ability to access to meta-technology. This finding could be explained by subsequent observations that China, at the time of our analysis, did not have well-established intellectual property rights and formal drug approval procedures; these two factors are important driving forces for developing joint ventures with foreign investors to gain additional capital funding and technology transfer. Broadly speaking, our results are consistent with the subsequent shakeup in the Chinese pharmaceutical industry.